Skip to content

GROW (Glioma Specialists Reaching Out With Support) Support

GROW Support (Glioma Specialists Reaching Out With Support): Assessment of a Comprehensive Support Program for Low Grade Glioma Patients Post-treatment

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05233215
Enrollment
0
Registered
2022-02-10
Start date
2022-07-31
Completion date
2024-06-15
Last updated
2023-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Care Giving Burden, Low-grade Glioma, Survivorship

Keywords

Low-grade Glioma, Survivorship, Care Giving Burden

Brief summary

This research study is being done to test a participant and caregiver-driven model of follow-up survivorship care,GROW Support (Glioma Specialists Reaching Out With Support), for post-treatment, low grade glioma patients.

Detailed description

This research study is a Feasibility Study, which examines if a supportive intervention for people with low grade gliomas (LGGs) and their caregivers is acceptable and feasible to patients and their caregivers. The research study procedures include: screening for eligibility and study interventions including filling out questionnaires and virtual or in-clinic supportive follow up visits to identify additional supportive needs that may arise. Participants will be in this research study for up to 6 months. It is expected that about 40 people will take part in this research study. The Levitan-Zabin Fund for GROW Support is supporting this research study by providing funds for research team members to do this study.

Interventions

BEHAVIORALGROW (Glioma Specialists Reaching Out With Support) Support Program

Follow-up survivorship care plan for patients and caregivers

Sponsors

Dana-Farber Cancer Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient inclusion criteria include: * Must be at least 18 years of age; * Diagnosed with low grade glioma (WHO grade 1 or 2) * Completed active treatment within the last 2 years and are undergoing surveillance follow-up * Must have at least one caregiver willing to participate as indicated below * Read and comprehend English such that they are able to complete required intervention sessions and psychosocial battery in English and are able to understand and willing to sign an electronic informed consent document. * Confirms willingness to undergo initial and follow-up questionnaire battery. * Caregiver inclusion criteria include: * Must be at least 18 years of age * Read and comprehend English such that they are able to complete required intervention sessions and psychosocial battery in English and able to understand and willing to sign an electronic informed consent document * Consider themselves personally involved in the patient's care and decisions about the care they receive.

Exclusion criteria

* Bipolar disorder, * Psychotic disorders and * Confusion or altered mental state that would prohibit understanding and giving of informed consent. However, if the patient's bipolar disorder or psychotic disorder is currently treated/managed, the patient will be eligible for the study.

Design outcomes

Primary

MeasureTime frameDescription
Retention Rate6 monthsPrimary outcome is feasibility as defined by 60% of the eligible participants and their caregivers being recruited into the study and completing the initial assessment and associated survivorship plan

Secondary

MeasureTime frameDescription
Abbreviated Acceptability Rating Profile6 monthsAcceptability of this supportive program (GROW Support) for patients and their caregivers will be assessed by the Abbreviated Acceptability Rating Profile and based on in-depth semi-structured interview with one of the study investigators.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026